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Summary
Ketoreductase (KR) activities help determine the ste-
reochemistry of the products of modular polyketide
synthases (PKSs). For example, domains eryKR1 and
eryKR2, contained, respectively, in the first and second
extension modules of the erythromycin-producing
PKS, reduce 3-ketoacyl-thioester intermediates with
opposite stereospecificity. Amino acid motifs that
correlate with stereochemical outcome have been
identified in KRs. We have used saturation mutagene-
sis of these motifs in eryKR1 and eryKR2, and a micro-
plate-based screen of such mutants for activity against
(9R, S)-trans-1-decalone, to identify candidate en-
zymes potentially altered in stereocontrol. Active mu-
tants were reassayed with (2R, S)-2-methyl-3-oxopen-
tanoic acid N-acetylcysteamine thioester, and the
alcohol products were analyzed by chiral HPLC. Vari-
ant enzymes were found with either altered substrate
selectivity for the (2R) or (2S) substrate or altered ste-
reospecificity of reduction, or both, further highlight-
ing the importance of these motifs in stereochemical
control.
Introduction
Modular type I polyketide synthases (PKSs) are multien-
zymes that catalyze the assembly line biosynthesis of
structurally complex and clinically important polyketide
natural products [1, 2], starting from simple carboxylic
acid building blocks. Each modular PKS is composed
of multiple enzyme domains, arranged into modules
that assemble the carbon chain by a mechanism resem-
bling that of fatty acid synthases: an acyltransferase (AT)
domain loads a dicarboxylic acid extender unit onto an
acylcarrier protein (ACP) domain, where it undergoes
condensation with a starter acyl unit in a reaction cata-
lyzed by a ketosynthase (KS). The product is an ex-
tended b-ketoacyl thioester intermediate that remains
covalently linked to the ACP. The b-keto group may
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Switzerland.then be processed by additional domains within the
module before the extended chain migrates to a KS for
another cycle of extension. Such reductive activities
are optionally present depending on the module and
comprise: a b-ketoreductase (KR) domain, which cata-
lyzes the reduction of the initially formed b-ketoester
to a b-hydroxyester; a dehydratase (DH) domain, which
dehydrates the b-hydroxyester; and an enoylreductase
(ER) domain, which reduces the double bond. The diver-
sity of polyketide structures results, in part, from combi-
natorial use of chemically different starter and extender
units, and, also, partly from the variable degree of pro-
cessing of b-keto groups. Extensive engineering of poly-
ketide biosynthetic genes [3–6] (including other en-
zymes in these pathways such as glycosyltransferases
[7]) has already resulted in the production of significant
additional molecular diversity. Chiral centers in complex
polyketides are introduced by the use of branched ex-
tender units and by the reduction of b-keto groups to al-
cohols. The ability to manipulate the stereochemistry of
the methyl and alcohol groups would give access to
many additional novel polyketides, perhaps with novel
clinical properties.
The most well-studied PKS, 6-deoxyerythronolide B
synthase (DEBS), catalyzes the synthesis of the macro-
lide precursor to the antibiotic erythromycin [8, 9]. The
AT domains of DEBS load (2S)-methylmalonyl groups
onto the ACP domains [10, 11], and condensation oc-
curs with inversion of stereochemistry at the carbon
atom derived from C-2 of the extender unit; thus,
a (2R)-2-methyl-3-ketoacylthioester is generated [12].
In certain PKS modules, such as extension module 1
of DEBS, the initial condensation product is epimerized
to give a (2S)-2-methyl-3-ketoacyl chain before reduc-
tion [12, 13]. In modules housing epimerizing KS do-
mains, such as extension module 1 of DEBS, the KR
also determines the methyl stereochemistry at C-2 by
discriminating between (2R)- or (2S)-2-methyl-3-ke-
toacyl substrates [14]. The engineered exchange of KR
domains between natural PKSs has shown that a KR do-
main in a PKS multienzyme may have an intrinsic stereo-
specificity and stereoselectivity (see, for example, [15,
16]). However, when confronted by ‘‘unnatural’’ sub-
strates, the stereochemical outcome is not always as
predicted, either in vivo or in vitro [17].
Individual KR domains of modular PKSs have recently
been successfully expressed as soluble and enzymati-
cally active proteins in recombinant Escherichia coli, in
the absence of other PKS components [18]. The kinetics
and stereochemistry of ketoreduction of model sub-
strates on these recombinant KR domains supported
the idea that alternative modes of binding to the KR ac-
tive site were responsible for different stereochemical
outcomes, and they revealed that the energetic differ-
ences between these binding modes are rather small.
It appeared, therefore, that alteration of only a few key
residues at the active site might suffice to change the
stereochemistry of KR-mediated reduction.
There is as yet no high-resolution X-ray crystal struc-
ture for any KR domain from a modular type I PKS.
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panying paper in this issue of Chemistry & Biology) has
shown that these enzymes belong to the short-chain de-
hydrogenase/reductase (SDR) family of NADPH-linked
dehydrogenases [21], in which proton transfer is thought
to occur from a conserved tyrosine to the carbonyl oxy-
gen of the substrate, while reaction intermediates are
stabilized by hydrogen bonding with a conserved serine
and lysine. The active site tyrosine and serine residues
are present in analogous positions in all modular PKS
KRs. Experimental confirmation for this assignment to
the SDR family has also been obtained by site-directed
mutagenesis of catalytic residues in the KR of DEBS
module 6 (eryKR6) [19]. Further, the multiple alignment
of natural KR domains catalyzing a known stereochem-
ical outcome has revealed that, at two positions near the
KR active site (referred to here as motif I and motif II, re-
spectively), the presence or absence of certain amino
acids is highly correlated with the stereochemistry of
the alcohol center, hinting at their possible contribution
to the mechanism of stereocontrol [22]. In the accompa-
nying paper [20], we report the effects of site-specific
mutagenesis of the residues in motifs I and II in eryKR1
and eryKR2, the KR domains derived, respectively,
from the first and second extension modules of DEBS.
These KR domains catalyze the production of alcohols
of opposite stereochemistry, although their active sites
have exactly the same architecture of catalytic residues
[20]. Remarkably, substitution of only two active site res-
idues in eryKR1 led to an effective switch of alcohol ste-
reochemistry. The results of mutation of eryKR2, which
normally encounters a triketide substrate and which is
not fully stereoselective against diketide substrates,
also showed significant changes in stereochemical out-
come [20].
There is currently great interest in using the methods
of molecular evolution [23–25] to achieve alterations or
improvements in the enantioselectivity and stereospec-
ificity of enzyme catalysis [26, 27]. These powerful
methods, which do not require precise information
about mechanism or active site structure, have not pre-
viously been applied to PKS multienzymes, but we rea-
soned that they might be applied to individual recombi-
nant domains. We report here the development of
a convenient microplate assay for activity of isolated
KR domains, suitable for high-throughput mutagenesis.
It is based on assays originally developed for fatty acid
synthase [28] and PKS [29] KR domains in their multien-
zyme context, and it was more recently used with re-
combinant PKS KR domains individually expressed in
Escherichia coli [18]. Catalytically competent enzymes
were isolated by screening thousands of mutants of
eryKR1 and eryKR2 that had been generated by satura-
tion mutagenesis of amino acid residues in motifs I
and II. Numerous active site mutants of both eryKR1
and eryKR2 that were active against surrogate sub-
strates and that had altered stereocontrol were identi-
fied. In addition to shedding light on the potential role
of individual active site residues, these results open
the way to directed molecular evolution of KR domains
via several rounds of mutation and selection, and to in-
sertion of such mutated KR domains into PKS multien-
zymes as a potential new route to engineered polyketide
drugs with altered chirality.Results and Discussion
Screening Libraries of eryKR1 and eryKR2
The first two ketoreductase domains from 6-deoxyery-
thronolide B synthase (DEBS), eryKR1 and eryKR2, pro-
duce opposite stereochemistry in terms of both the
methyl and alcohol centers in the macrolide product
(see Figure 1 of the accompanying paper [20]). Using
the classification system of Caffrey [22], eryKR1 is B
type and eryKR2 is A type, corresponding to reduction
from alternative faces of the keto group. The actual ste-
reochemical course for reduction of the surrogate sub-
strate (2R, S)-2-methyl-3-ketopentanoic acid N-acetyl-
cysteamine thioester has been previously shown to be
as in Figure 1. eryKR1 selects the (2S)-enantiomer of
the substrate and reduces it almost exclusively to the
(2S, 3R) product, as predicted, while, for eryKR2, the
predicted product is only a few percent of the product
mixture [18]. Broadly, mutagenesis of eryKR1 was there-
fore expected to lead to a loss of stereocontrol, while,
for eryKR2, no clear prediction could be made. Figure 1
also shows the reaction that both eryKR domains cata-
lyze on (9R, S)-trans-1-decalone [28, 29].
Three residues in each motif were chosen for satura-
tion mutagenesis: residues 93–95 in motif I, and residues
141, 144, and 148 in motif II (amino acids are numbered
according to [22]). Each motif was randomized in each
enzyme to give four libraries (libraries 4–7, Figure 2),
and the three residues making up motif I in KR1 were
also diversified singly in three smaller libraries (libraries
1–3, Figure 2). The change in absorbance of the cofactor
NAPDH provided a convenient spectrophotometric as-
say for ketoreductase activity against (9R, S)-trans-1-
decalone. The assay was optimized for use with unpuri-
fied proteins in a 96-well microplate format (Figure 3A);
96 members each of libraries 1–7 (except for libraries 4
and 5; 288 members) were screened for ketoreductase
activity (Figures 3B–3H). The frequency of clones active
against decalone is summarized in Figure 2. Several ac-
tive mutants from libraries 1–7 were chosen for further
characterization.
Screening for Compensating Mutations
in Site-Directed Mutants of eryKR1 and eryKR2
Four recombinant KR domains have previously been
constructed by mutagenesis to either motifs I and II:
KR1 WGG, KR1 PQS, KR2 LDD, and KR2 LPN [20]. Of
these four enzymes, only KR2 LDD is sufficiently active
for detection by the microplate assay. We were inter-
ested to discover whether the catalytic defects in these
enzymes could be compensated by mutations at the
other motif, and diversity was therefore introduced to
each mutant (Figure 2) to give an additional seven li-
braries equivalent to libraries 1–7, but with fixed muta-
tions at the undiversified motifs. A total of 288 mem-
bers of each library were screened. Mutants with
improved activity toward decalone were isolated from
libraries 10 (KR1 WGG 95), 12 (KR1 PQS 141–148),
and 14 (KR2 LPN 93–95) (a single mutant from each li-
brary), and 13 (KR2 LDD 141–148) (8.3% of members
are active) (Figure 1). No active variants were found in
libraries 8 (KR1 WGG 93), 9 (KR1 WGG 94), or 11 (KR1
WGG motif I).
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289Figure 1. Surrogate Substrates Used in This
Work for In Vitro Assay of Recombinant
Ketoreductase Domains Derived from the
Erythromycin-Producing PKS
(A–C) Surrogate substrates used in this
work for in vitro assay of recombinant keto-
reductase (KR) domains derived from the
erythromycin-producing PKS. (A) Reduction
of racemic 2-methyl-3-ketopentanoic acid
N-acetylcysteamine thioester (1) by eryKR1
and by eryKR2. eryKR1 reduces the (2S) ste-
reoisomer of 1 only and produces almost ex-
clusively the predicted diastereoisomer of
the product, 2 [18, 20]. (B) eryKR2 produces
a mixture of three diastereomers, 2, 3, and
5, in which the predicted product, 5, is a mi-
nor component [18, 20]. (C) Reduction of
(9R, S)-trans-1-decalone by either eryKR1
or eryKR2 [29].Characterization of Selected KRs
Selected genes were sequenced, and the KR domains
were purified as fusion proteins with glutathione-S-
transferase (GST) for in vitro assays, as described previ-
ously [18]. The fusion proteins were used directly in these
experiments, since we have previously shown [18] that
the presence of the GST domain does not significantly
affect the kinetics or stereochemistry of KR-mediated re-
duction. Reaction rates with decalone were measured
spectrophotometrically. (2R, S)-2-methyl-3-ketopenta-
noic acid N-acetylcysteamine (NAC) thioester was used
as a model substrate to determine the reaction stereo-
specificity, by HPLC analysis of the products. The results
are summarized for eryKR1 in Table 1, and for eryKR2 in
Table 2, and the HPLC separation of the alcohol stereo-
isomers is shown in Figure 4. Although the mutants de-
rived from KR1 WGG (library 10) and KR1 PQS (library
12) had higher activity toward decalone, they were inac-
tive with NAC-diketide, and they are not included here.
Some eryKR1 mutants showed a reversal of stereospec-
ificity (Figure 5) accompanied by a decrease in overall ac-
tivity, as has been seen for certain specific mutants of
this enzyme [20]. The effects of individual mutations
are interpreted below with reference to recent structural
models of eryKR1 and eryKR2 [20].Prescreening of eryKR Mutants for Reduction
of Decalone Allows for Rapid Identification
of Mutants Capable of NAC-Diketide Reduction
In the present work, the theoretical total library size was
262,144 mutant genes for eryKR domains, encoding
64,000 different proteins. In practice, some of the librar-
ies made were incomplete; for example, library 4 theoret-
ically comprises 32,768 genes, but only 10,000 colonies
were picked. Nevertheless, a representative sample of
over 100,000 mutant genes was constructed, and over
2,000 of these proteins were screened by using the
NADPH-linked assay. The separation of KR domains
from their context in the PKS multienzyme requires the
use of surrogate, untethered substrates for assays.
NAC-diketide could also be used in the microtitre
plate-based screen, but the use of the cheaper, more
stable, decalone allowed for the rapid examination of
large numbers of KRs. Despite the obvious differences
between the two types of substrate, preselection of li-
braries for decalone reduction was shown to increase
the likelihood of isolating mutants capable of NAC-dike-
tide reduction (see the Supplemental Data available with
this article online). Nevertheless, any mutants possess-
ing activity toward NAC-diketide, but lacking decalone
reductase activity, would have been discarded during
Chemistry & Biology
290Figure 2. Homology Model of the Active Site of PKS Ketoreductase Domains
(A and B) The model of the active site of ketoreductase eryKR1 [20] shows catalytic residues (in red) and amino acid motifs identified by Caffrey
[22], which are putatively involved in the control of stereochemistry by KR domains from modular PKSs. (A) The strongest indicator for B-type
KR domains is an LDD motif (motif I) in the region between amino acids 88 and 103, which is absent from A-type KR domains. Additional amino
acids in the 134–149 region (motif II) support this assignment, specifically P144 and N148, which indicate B-type KRs and W141 in A-type do-
mains. The active site Y149, S136, and K153 (red) position the substrate carbonyl for the transfer of the hydride by NADPH (cyan). F141, P144,
and G148 are part of a loop directly adjacent to catalytic residue Y149, while LDD93–LDD95 belong in a loop adjacent to the active site (blue).
(B) Sequence alignment of KR domains showing the site-directed mutations constructed in this work. The active site motifs, and the changes
made, are indicated in bold (residues are numbered according to [22]). X indicates randomized residues.the screening. This is a common drawback of surro-
gate substrates in directed evolution: multiple rounds
of mutagenesis and selection favor enzymes that are
best adapted to the surrogate, which may not neces-
sarily be the best with the real substrate. Future work in-
volving multiple rounds of screening and selection
should preferably be based on more realistic substrate
mimics.
Mutants showing activity toward decalone were found
to comprise a few percent of each library (Figures 2 and
3). These proteins must be stable and well expressed,
with unperturbed catalytic residues and a NADPH
binding site. The sequences of mutants that meet these
requirements form a consensus of amino acid combina-
tions for active KRs. In eryKR1 motif I, all three positions
contained a high proportion of hydrophobic residues,
particularly tryptophan (Table 1). In motif II, residue 141was usually hydrophobic, and residue 144 was always
proline or serine. A variety of mutations were seen in po-
sition 148, but mutants with alanine or glycine had the
highest activity toward NAC-diketide. In eryKR2 motif I,
there appears to be a high proportion of hydrophilic
residues, though only three mutants were examined. In
motif II, residue 141 is hydrophobic, residue 144 is pro-
line or hydrophobic, and residue 148 is alanine or glycine
(Table 1).
None of the residues studied are intolerant to muta-
tion, confirming that they do not play a direct role in
NADPH binding or catalysis. Leucine 93 of eryKR1 is
the least tolerant to mutation, consistent with its position
in the structural model—only 4 A˚ from the catalytic tyro-
sine 149. Mutations in both motifs modulate eryKR1
and eryKR2 activity and may increase or decrease the
activity toward decalone; for example, eryKR1 (D95M)
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291Figure 3. Screening Expression Libraries for
Ketoreductase Activity
(A–H) Decalone reduction by KR was de-
tected in cell extracts of recombinant
E. coli. Absorption at 340 nm was measured
for a period of 20 min. (A) Measurement of
NADPH consumption by E. coli expressing
eryKR1 (triangles), eryKR2 (squares), or no
KR (circles). The other panels show mea-
surements of NADPH consumption by cell
extracts containing mutant KRs, 96 samples
per panel. (B) 96 clones from library 1 KR1
residue 93. (C) Library 2 KR1 residue 94. (D)
Library 3 KR1 residue 95. (E) Library 4 KR1
motif I residues 93–95. (F) Library 5 KR1 motif
II residues 141, 144, and 148. (G) Library 6
KR 2 motif I residues 93–95. (H) Library 7
KR 2 motif II residues 141, 144, and 148.has 6-fold higher activity. This suggests that the residues
concerned are indeed close to the active site and are in-
volved in substrate binding or orientation. A possible al-ternative explanation is that they may affect a conforma-
tional transition between open (unbound) and closed
(substrate bound) forms of the enzyme, analogous toTable 1. Activity and Specificity of KR1 Mutants against Decalone and (2R, S)-2-Methyl-3-Oxopentanoic Acid NAC Thioester Substrates
Library Motifs I and II
Activity against
Decalonea
Peak Area,
(2R, 3R) (4)
Peak Area,
(2S, 3S) (3)
Peak Area,
(2S, 3R) (2)
KR1
b LDD FPG 0.260 298 198 32,469
Motif I Single Mutants
WDD FPG 0.079 110 110 468
LRD FPG 0.057 332 513 735
LSD FPG 0.163 196 377 3,849
LWD FPG 0.154 170 351 4,124
LDA FPG 0.141 335 516 560
LDM FPG 1.614 192 373 180
LDR FPG 0.052 318 499 408
LDV FPG 0.797 nd 245 101
Motif I Triple Mutants
AHM FPG 0.148 129 310 4,136
ARM FPG 0.172 105 294 1391
LWRc FPG 0.147 543 724 289
MWCc FPG 0.065 565 746 239
VGR FPG 0.333 118 299 5,250
WEW FPG 0.148 101 282 154
WRP FPG 0.080 451 632 628
WWAc FPG 0.208 677 858 478
Motif II
LDD FPS 0.215 462 643 54,550
LDD YPA 0.787 458 639 51,503
LDD ASA 1.190 nd 193 34,113
LDD TSG 0.110 319 500 26,853
LDD FSA 0.279 nd 209 23,634
LDD HPE 0.537 300 481 12,414
LDD GPI 0.182 356 537 10,769
LDD ASR 0.269 nd 141 756
Amino acid residues within either motif I or motif II that were found to be altered in each KR mutant are shown in bold type.
a Units of activity are mmoles/min/mg protein, measured at 5 mM decalone, 40 mM NADPH, and 0.2 mg/ml KR.
b Higher column loading allowed for detection of these minor products of KR1, not reported by Siskos et al. [18]. nd indicates that a peak was not
detected for this isomer.
c The products of ketoreduction of 1 by these mutants (which show inverted stereospecificity) are shown in Figure 5. Specific activity of wild-type
KR1 with NAC-diketide is 0.06 mmoles/min/mg protein.
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292Table 2. Activity and Specificity of KR2 Mutants against Decalone and (2R, S)-2-Methyl-3-Oxopentanoic Acid NAC Thioester Substrates
Library Motifs I and II
Activity against
Decalonea
Peak Area,
(2S,3S) (3)
Peak Area,
(2R,3S) (5)
Ratio (2S,3S):
(2R,3S)
Peak Area,
(2S,3R) (2)
KR2
b PQQ WAA 0.074 1,968 515 3.8:1.0 1,059
Motif I
LDD WAA 0.411 6,409 2,189 2.9:1.0 nd
KEN WAA 0.095 931 178 5.2:1.0 nd
LKR WAA 0.097 1,555 1,096 1.4:1.0 nd
Motif II
PQQ LPN 0.009 2,898 3,164 1.0:0.9 nd
PQQ LPA 0.015 30,731 13,259 2.3:1.0 nd
PQQ LPG 0.016 22,670 9,266 2.4:1.0 nd
Both Motifs LDD LPN — 4,872 4,404 1.1:1.0 nd
Motif I LDD, II Selected
LDD CFG 0.143 6,381 6,325 1.0:1.0 nd
LDD FLG 0.135 12,973 7,009 1.9:1.0 nd
LDD FPG 0.132 15,313 8,193 1.9:1.0 nd
LDD IPA 0.083 6,434 11,524 1.0:1.8 nd
LDD LAG 0.081 10,233 8,193 1.2:1.0 nd
LDD WCG 0.457 6,324 3,124 2.0:1.0 nd
II LPN, I Selected MKK LPN 0.056 15,398 51,366 1.0:3.3 nd
Amino acid residues within either motif I or motif II that were found to be altered in each KR mutant are shown in bold type.
a Activity is expressed in mmoles/min/mg protein, measured at 5 mM decalone, 40 mM NADPH, 0.2 mg/ml KR.
b Specific activity of wild-type KR2 with NAC-diketide is 0.07 mmoles/min/mg protein. nd indicates that a peak was not detected for this isomer.the transition reported for the KR involved in biosynthe-
sis of the aromatic polyketide actinorhodin [30, 31].
Mutants of eryKR1 Isolated from the
High-Throughput Assay Include Variants
Having Switched Stereospecificity
of Ketoreduction
The most telling evidence for the direct involvement of
the targeted residues in substrate binding comes
from the examination of the stereospecificity of individ-
ual mutants against (2R, S)-2-methyl-3-oxopentanoic
acid NAC thioester as substrate. Wild-type eryKR1
yields the (2S, 3R) isomer of the alcohol as the major
product (>98%) (Figure 1), as predicted from the struc-
ture of erythromycin, and as observed in the intact mod-
ule. Trace amounts of the (2S, 3S) and (2R, 3R) isomers
were also obtained. All mutations to motif I of eryKR1
dramatically reduce the yield of the (2S, 3R) isomer,
sometimes to the limits of detection (Figures 4B and
4C). Since all of the selected enzymes have high activity
toward decalone, there are two possible interpretations
of the dramatic loss of activity toward (2R, S)-2-methyl-
3-oxopentanoic acid NAC thioester. First, the residue(s)
in question might be involved in binding the substrate.
Alternatively the substitution may simply block access
to the active site, particularly if bulky residues, for exam-
ple, L93W, are involved. For residue D95, the first expla-
nation seems the more likely, as four different substitu-
tions, including an alanine, all have the same effect
(Table 1). The reduction in activity is dramatic, over 50-
fold, which would be consistent with a direct interaction,
for example, via a hydrogen bond, between D95 and the
substrate. In contrast, the yield of the ‘‘wrong’’ alcohol
stereoisomer, (2S, 3S), is unchanged by several muta-
tions to motif I, and some mutations actually increasethe yield by up to 4-fold. In mutants in which the yield
of the (2S, 3R) isomer is very low, for example, in mu-
tants containing tryptophan in motif I, the (2S, 3S) isomer
is the major product (Figure 5). In other words, the ste-
reospecificity of reduction is reversed, as reported for
specific eryKR1 mutants in the accompanying paper
[20]. Such mutants confirm that the (2S, 3R) and (2S,
3S) isomers are likely to have arisen from two different
binding modes of the NAC-diketide, involving different
substrate-protein interactions, rather than alternative
positioning of the catalytic tyrosine.
Motif II of eryKR1 is more tolerant to mutation than is
motif I, with retention of reductase activity toward
NAC-diketide. In particular, the triple mutant ‘‘ASA’’ (Ta-
ble 1) has activity and stereochemistry comparable to
wild-type eryKR1 (Figure 4D). In general, the amino
acid requirements for decalone reduction are the same
as those for diketide reduction, which may represent
the requirements for enzyme folding or stability, and
there is no evidence for a direct role in substrate binding.
The tolerance of eryKR1 to mutations at position 148 is
surprising, as this residue is adjacent to the catalytic
residue Y149 and it is intolerant to mutation in eryKR2.
Bulky residues at this position appear to decrease the
activity toward NAC-diketide more severely than toward
decalone, as seen with ‘‘ASR,’’ which has 5-fold lower
activity against decalone than ‘‘ASA,’’ but 45-fold lower
activity against NAC-diketide.
Mutants of eryKR2 Isolated from the
High-Throughput Assay Include Variants
with Increased Stereospecificity and Activity
of Ketoreduction against Surrogate Substrates
Wild-type eryKR2 has been reported [18, 20] to reduce
(2R, S)-2-methyl-3-oxopentanoic acid NAC thioester to
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(2S, 3S) isomer (wrong substrate selectivity), and the
(2S, 3R) isomer (wrong substrate selectivity and wrong
product specificity), with the (2S, 3S) isomer forming
the main product (Figure 1). Surprisingly, all mutants of
eryKR2 yielded only 3S alcohols (correct specificity),
with 2R or 2S methyl centers in variable proportion (Fig-
ures 4E and 4F; Table 2). Mutations at motifs I and II ap-
pear to fix the stereospecificity and manipulate the sub-
strate selectivity. This result must be treated with
caution, however, as (2R, S)-2-methyl-3-oxopentanoic
acid NAC thioester is a poorer substrate mimic for
eryKR2. It is also shorter than the triketide chain normally
acted on by eryKR2 in the context of the PKS, and it is
a mixture of both 2S and 2R isomers, whereas eryKR2
is normally preceded by a nonepimerizing KS and is,
Figure 4. Stereochemical Outcome of Ketoreduction by eryKR1,
eryKR2, and Selected Mutants
(A–F) HPLC traces showing the separation of the stereoisomers of
2-methyl-3-hydroxypentanoic acid NAC thioester. Each trace rep-
resents 20 min of elution time. Synthetic samples of all four isomers
were used as standards and are shown at the bottom of each panel
(‘‘Mix’’). The same standards were used in all panels, but the scale
of each panel is adjusted according to the yield of product. (A) Re-
action products of wild-type KR1 and KR2. (B) KR1 mutants se-
lected from libraries 1–3. Amino acids 93–95 of motif I are shown
next to each trace. (C) KR1 mutants from library 4, motif I. (D) KR1
library 5, motif II amino acids 141, 144, 148. (E) KR2 mutants from
libraries 5 and 6 and designed mutants, motifs I and II. (F) KR2 mu-
tants from libraries 13 and 14, motifs I and II.hence, presented with only 2R substrates. Nevertheless,
it is interesting that the majority of eryKR2 mutants were
more active than the wild-type, with either decalone or
(2R, S)-2-methyl-3-oxopentanoic acid NAC thioester 1
as substrate. This is difficult to rationalize, apart from
the observation that the mutations remove bulky resi-
dues, either proline 93 or tryptophan 141, or both. It is
possible that the mutants have a more open active site
or are more flexible, but further interpretation will require
structural data. No single residue was absolutely essen-
tial for (2R, S)-2-methyl-3-oxopentanoic acid NAC thio-
ester reduction by eryKR2. However, the observation
that mutations in motifs I or II may alter, or even reverse,
the substrate selectivity clearly implicates both motifs in
substrate binding.
Conclusions
Directed evolution has proved a potent tool for the se-
lection of enzyme variants with desirable properties, in-
cluding increased activity against alternative sub-
strates, higher thermostability, and reduced product
inhibition [25]. A number of complementary techniques
have been used to generate enzyme variants, including
introduction of single changes by (for example) error-
prone PCR, saturation mutagenesis of active sites, and
DNA shuffling [23], and these have been fruitfully com-
bined with rational design approaches [25]. Some of
the most interesting recent advances concern the ma-
nipulation of the stereochemical outcome of catalysis.
Figure 5. HPLC Separation of the Products of Reduction of a Surro-
gate Substrate by Recombinant PKS Ketoreductase Domains
HPLC separation of the products of reduction of (2R, S)-2-methyl-
3-oxopentanoic acid N-acetylcysteamine thioester 1 by eryKR1
mutants that show reduced catalytic activity but reversed stereo-
specificity compared to wild-type. The peaks corresponding to in-
dividual stereoisomers of 2-methyl-3-hydroxypentanoic acid NAC
thioesters 2, 3, and 4 are indicated by arrows. The amino acid se-
quence found at positions 93–95 in each mutant is shown next to
the corresponding trace.
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hance the enantioselectivity of a lipase acting on a chiral
ester [32] and also to invert the enantioselectivity of the
enzyme, via a total of only 11 amino acid substitutions
[33]. Subsequent analysis has shown, importantly, that
these changes affect not only active site residues, but
also more remote residues [26]. However, the residues
at the active site still provide a promising starting point
for attempts to alter stereoselectivity. Of particular rele-
vance to the stereochemistry of reduced or complex
polyketides is the role of ketoreductase enzymes. Re-
cent work on two mutually homologous plant tropinone
reductases, which reduce the same alkaloid substrate,
tropinone, to different stereoisomeric alcohols [34],
has shown that their active site geometry is highly con-
served, and that the stereospecificity may be switched
by site-directed mutagenesis of only a few residues at
the active site [35].
Until now, directed evolution has not been applied to
polyketide synthases, although attempts have been
made to speed up the construction and screening of hy-
brid PKS multienzymes [36, 37]. The enormous size of
PKS genes and their content of multiple copies of highly
repetitive DNA offer a particular technical challenge. In
this work, we have taken advantage of the recent finding
that individual KR domains from modular PKSs can be
expressed as separate and active enzymes, making
them accessible to high-throughput methodology. As
for tropinone reductases, the PKS KR domains all share
a common architecture, and, in the accompanying pa-
per [20], we provide evidence that mutagenesis of amino
acid residues in certain motifs at the active site of the
eryKR1 and eryKR2 domains significantly alters the ste-
reochemical outcome of catalysis. The results of the pres-
ent paper provide strong additional evidence for the
importance of these residues in stereocontrol, and dem-
onstrate the potential for molecular evolution applied to
individual domains of an assembly line multienzyme.
The combination of saturation mutagenesis and high-
throughput screening has enabled scrutiny of the KR ac-
tive site in far more detail than conventional techniques
allow. This has given additional support to a model for
catalysis in which the enantioselectivity and stereospec-
ificity of reduction are dictated by different binding
modes of each substrate to a catalytic apparatus in
the KR active site whose geometry is essentially identi-
cal in both eryKR1 and eryKR2 [19, 20]. It also has al-
lowed rapid confirmation of the potentially useful finding
made in the accompanying paper [20] that the stereo-
chemistry of ketoreduction can be effectively switched
by exchange of only a few active site residues. These
were residues that had been previously highlighted as
being correlated with a given stereochemical outcome
in natural PKS KR domains [19, 22]. It remains to be
seen whether such mutant KRs retain their altered prop-
erties when inserted into modular PKS multienzymes. If
so, this approach may offer a promising new route to the
production of novel polyketide products. The same ap-
proach could evidently be taken for the constituent do-
mains/activities of nonribosomal peptide synthetase
multienzymes, in which the directed evolution of the en-
tire multienzyme also presents a challenging prospect.
A practical consideration is the significant loss of cat-
alytic activity in many mutants studied, compared to thewild-type enzyme. Encouragingly, typical PKS KR do-
mains have measured catalytic activities in vitro 1–2 or-
ders of magnitude higher than those reported for the op-
eration of an intact modular PKS multienzyme [16, 18,
20, 29]; thus, even mutant KR domains with compro-
mised activity may not decrease the rate of overall poly-
ketide synthesis. The present work also opens the way
for directed evolution of KRs, via multiple rounds of mu-
tagenesis and selection. This could also reveal further
mutations, remote from the active site [26], which con-
tribute to stereocontrol, and it can provide improved
variants for installation in PKS assembly lines. Since
several other PKS-derived domains, including AT-ACP
[38, 39], KS-AT [40], and TE [41, 42] domains, have
also been shown to be active in vitro, these, too, are po-
tential targets for such directed evolution.
Significance
The engineering of modular polyketide synthases
(PKSs) by the creation of hybrid multienzymes, in
which domains and modules from two or more PKSs
are spliced together, has proved a versatile technol-
ogy for the rational production of novel, potentially
bioactive polyketides, but many such hybrids are in-
efficient. Altering the configuration of the polyketide
products has proved particularly difficult because we
lack detailed information about the mechanisms of
stereocontrol during polyketide chain extension. For
conventional single enzymes, in vitro-directed evolu-
tion has provided a uniquely powerful approach to ob-
tain altered enzyme catalysts, particularly when com-
bined with rational design. Such methods are not
easy to apply to giant assembly line multienzymes
such as PKSs and nonribosomal peptide synthetases
(NRPSs). We have developed a convenient method for
high-throughput saturation mutagenesis and assay of
individual ketoreductase (KR) domains from a modular
PKS, and we have used it to identify active mutants,
out of some 2000 mutants assayed, with the desired al-
tered stereocontrol. The results support our current
model for stereochemical control of KR-catalyzed ke-
toreduction, and they encourage the view that directed
evolution of individual domains is a fruitful approach
to understanding and altering the catalytic properties
of engineered polyketide synthases.
Experimental Procedures
Library Construction
Libraries were constructed by PCR with oligonucleotides to encode
randomized residues with the codon NNS, where N = A, G, C, or T
and S = G or C (sequences of oligonucleotides are provided in Sup-
plemental Data). The templates were KR1 and KR2 cloned in
pGEX-4T-3, or mutants of these enzymes. Libraries were prepared
in E. coli strain DH10B [43, 44], and the library size was determined
by counting the number of colonies. Colonies were scraped up for
preparation of plasmid DNA.
Library Screening
Plasmids were transformed in E. coli BL21-CodonPlus-RP (Strata-
gene), and individual colonies wer used to inoculate 1 ml LB medium
supplemented with ampicillin (100 mg/l) and chloramphenicol (30
mg/l) in a Deepwell 96-well plate (Fisher). Plates were sealed with
adhesive film, which was pierced with a fine needle (1 mm bore,
Saturation Mutagenesis of PKS KR Active Sites
295two holes per well). Master plates were grown at 30ºC with shaking
at 625 rpm for 22 hr, after which a small portion (10 ml) of each cul-
ture was used to inoculate a duplicate plate for expression. After
4.5 hr of growth at 30ºC, IPTG was added to a final concentration
of 0.1 mM, and, after growth for an additional 3 hr, cells were har-
vested by centrifugation, and the pellets were stored at220ºC. Cells
were resuspended in 200 ml lysis buffer (50 mM sodium phosphate
[pH 8.0], containing 150 mM sodium chloride, 1 mg/ml lysozyme,
and 3 U/ml Benzonase [Novagen]). Lysates were incubated at
25ºC for 5 min and transferred to 96-well Optical Reaction Plate (Ap-
plied Biosystems), and the insoluble fragments were removed by
centrifugation.
Cell-free extracts were used directly for activity assays by the ad-
dition of 50 ml cell-free extract to 50 ml reaction mixture (100 mM po-
tassium phosphate [pH 7.5], containing 1.6 mM NADPH and 10 mM
decalone) in a UV-transparent 96-well plate (Grenier). Reactions
were incubated at 30ºC in the chamber of a Spectramax Plus micro-
plate reader equipped with Softmax Pro (Molecular Devices, Phila-
delphia, PA) software for data acquisition and analysis, and absor-
bance at 340 nm was measured at 30 s intervals for 20 min. A total
of 35 active clones were chosen for further analysis.
To determine whether screening for decalone activity is an effi-
cient means of isolating mutants with (2R, S)-2-methyl-3-oxopenta-
noic acid NAC thioester reductase activity, four clones were chosen
from both libraries 10 (KR1 93–95) and 12 (KR1 141–148) without pre-
selection. These eight enzymes were purified and assayed in parallel
with the selected mutants (Supplemental Data). All eight were well
expressed, although only one shows significant activity with deca-
lone. Four of the mutants gave no detectable reduction of (2R, S)-
2-methyl-3-oxopentanoic acid NAC thioester, and the remaining
four yielded the (2S, 3R) isomer of the alcohol product in extremely
low yield (Supplemental Data).
Purification of KR Domains and Kinetic
and Stereochemical Analysis
Plasmid DNA was prepared from master plates, sequenced, and
used to transform E. coli BL21-CodonPlus-RP for expression. Ex-
pression and purification was as described in the accompanying pa-
per [20]. Activity was determined by both the addition of 50 ml protein
(0.2 mg/ml) to 50 ml reaction mixture and the measurement of the rate
of NADPH consumption, as described above. For product analysis,
reactions contained 0.1 mg/ml protein, 50 mM potassium phosphate
(pH 7.5), 8 mM NADPH, and 10 mM (2R, S)-2-methyl-3-oxopentanoic
acid NAC thioester. Reactions were started by the addition of pro-
tein and were incubated at 30ºC for 16 hr. Products were extracted
with ethyl acetate, dried, and dissolved in 50 ml isopropanol. Prod-
ucts were separated by HPLC with a Chiracel OC column (Chiral
Technologies Europe) in 93% isohexane, 7% ethanol as described.
Synthetic samples of (2R, 3R)-, (2S, 3S)-, (2R, 3S)-, and (2S, 3R)-3-
hydroxy-2-methylpentanoic acid were used as standards. The sub-
strate contained a minor impurity (0.2%, peak area 181) with the
same retention time as (2S, 3S)-2-methyl-3-oxopentanoic acid
NAC thioester, which was subtracted from all samples.
Supplemental Data
Supplemental Data including the synthetic oligonucleotides used in
the library construction as well as data on the sequence, activity,
and stereospecificity of randomly selected KR library members
are available at http://www.chembiol.com/cgi/content/full/13/3/
287/DC1/.
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